Q4 2025 Biofrontera Inc Earnings Call Transcript
Key Points
- Biofrontera Inc (BFRI) achieved record annual revenues of $41.7 million in 2025, marking a 12% growth over the previous year.
- The company reported a highly profitable fourth quarter with an adjusted EBITDA of $4.9 million and a net income of $5.6 million.
- Biofrontera Inc (BFRI) completed a strategic transaction with Biofrontera AG, acquiring full US rights to Ameluz and RhodoLED, which significantly improved their cost structure.
- The company secured $11 million in funding through a private placement, enhancing financial flexibility for future growth.
- Positive clinical trial results were reported for Ameluz in treating superficial basal cell carcinoma and actinic keratosis, with potential label expansions on the horizon.
- Despite improvements, Biofrontera Inc (BFRI) reported a net loss of $10.5 million for the full year 2025.
- Legal expenses increased significantly by $6 million due to patent claims, impacting overall financial performance.
- Research and development expenses rose to $3.7 million, reflecting increased responsibility for US clinical trials.
- The company experienced a churn rate, although the lowest since 2021, indicating some loss of business from previous accounts.
- Biofrontera Inc (BFRI) still faces risks and uncertainties associated with forward-looking statements and market conditions.
Welcome to the Biofrontera Inc. fourth-quarter and full-year 2025 financial results and business update conference call. (Operator Instructions) Please note, this event is being recorded.
I would now like to turn the conference over to Ben Shamsian with Lytham Partners Investor Relations. Please go ahead.
Thank you. Good morning, and welcome to Biofrontera's fourth-quarter and full-year 2025 financial results and business update conference call. Please note that certain information discussed during today's call by management is covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act.
We caution listeners that Biofrontera's management will be making forward-looking statements and that actual results may differ materially from those stated or implied by these forward-looking statements due to the risks and uncertainties associated with the company's business. All risks and uncertainties are detailed in and are qualified by the cautionary statements contained
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
